Saturday - May 17, 2025
HUNTSVILLE, Ala., Oct. 2, 2024 /PRNewswire/ -- Ambetter of Alabama, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will offer a variety of affordable health insurance plans to Alabamans in 39 counties for plan year 2025. Open enrollment for the Health Insurance Marketplace for Alabama runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15 for coverage starting Jan. 1, 2025.
Ambetter of Alabama offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include:
Below is a full list of counties in which Ambetter of Alabama will be offered in 2025:
Alabama residents interested in learning more about Ambetter of Alabama or enrolling in a health plan during the open enrollment period may visit ambetterhealth.com/en/al.
About Ambetter of Alabama
Ambetter of Alabama serves under-insured and uninsured populations through the federal Health Insurance Marketplace®. Ambetter of Alabama is underwritten by Celtic Insurance Company, which is a Qualified Health Plan issuer in Alabama. For more information, visit ambetterhealth.com/en/al. This is a solicitation for insurance. For information on your right to receive an Ambetter of Alabama plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$61.78 |
Daily Change: | 1.72 2.86 |
Daily Volume: | 4,143,686 |
Market Cap: | US$31.190B |
April 25, 2025 February 24, 2025 February 04, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load